Discontinued — last reported Q1 '20
A steady decline is expected due to amortization, while a sudden drop may signal an impairment charge reflecting reduced future earnings expectations.
This metric represents the unamortized book value of intellectual property, patents, or marketing rights associated spec...
Comparable to product-related intangible asset balances reported by other pharmaceutical firms with significant patent-protected portfolios.
biib_segment_avonex_finite_lived_intangible_assets_net